Brings together Recursion’s scaled biology exploration and translational capabilities with Exscientia’s precision chemistry design and small molecule automated synthesis capabilities to create a ...
Recursion Pharmaceuticals (NASDAQ: RXRX), a trailblazer in TechBio that is revolutionizing the field of drug discovery, has received a $50 million investment from NVIDIA (NASDAQ: NVDA). The ...
SALT LAKE CITY, May 15, 2018 /PRNewswire/ -- Recursion Pharmaceuticals, a biotechnology company that combines artificial intelligence (AI), experimental biology, and automation to discover drugs at ...
Unele rezultate au fost ascunse, deoarece pot fi inaccesibile pentru dvs.
Afișați rezultatele inaccesibile
Părere